Hipernatremi ve Hiperosmolar Hiperglisemik Durum ile Prezente Olan COVID-19 Olgusu

Year 2020, Volume: 12 Issue: 3, 92 - 94, 31.12.2020

Erkut Etçioğlu , Deniz Çekiç , Kubilay İşsever , Ahmed Cihad Genç , Esma Seda Çetin , Abdülkadir Aydın , Selcuk Yaylacı

https://doi.org/10.35514/mtd.2021.38

Abstract

Dünyada ilk SARS-CoV-2 enfeksiyonunun görülmesinden bu yana yapılan araştırmalar, bu enfeksiyonun pulmoner tutulumların yanında ekstrapulmoner tutulumlara da yol açtığını göstermiştir. COVID-19 hastalığı olan kişilerde; pankreas tutulumu olduğunda, akut hiperglisemik krizlere, diyabetik ketoasidoza (DKA) ve hiperosmolar hiperglisemik duruma (HHD), diyabetin ciddi akut metabolik komplikasyonlarına; renal tutulum gerçekleştiğinde ise akut böbrek hasarına ve elektrolit bozukluklarına yol açabildiği saptanmıştır. Bu yazıda; pulmoner tutulum belirtileri olmayan, hipernatremi ve hiperosmolar hiperglisemik durum ile prezente olan COVID-19 olgusu sunulmuştur.

Keywords

Hipernatremi, Hiperosmolar Hiperglisemik Durum, SARS-CoV-2, COVID-19

COVID-19 Presenting with Hypernatremia and Hyperosmolar Hyperglycaemic State: A Case Report

Abstract

Researches since the first SARS-CoV-2 infection in the world have shown that this infection causes extrapulmonary involvement as well as pulmonary involvement.. In people with COVID-19 disease; when pancreatic involvement occurs, acute hyperglycemic crises, diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), severe acute metabolic complications of diabetes; when renal involvement occurs, it has been found that it can lead to acute kidney damage and electrolyte disturbances. In this article; a COVID-19 case without signs of pulmonary involvement who presented with hypernatremia and hyperosmolar hyperglycemic state is presented.

Keywords

Hypernatremia, Hyperosmolar Hyperglycemic State, SARS-COV-2, COVID-19

References

• 1Gupta A, Madhavan M.V, Sehgal K, Nair N, Mahajan S, Sehrawat T.S, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020; 26(7):1017-1032. doi: 10.1038/s41591-020-0968-3. Epub 2020 Jul 10. PMID: 32651579.
• Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens Res. 2020; 43, 648–654. https://doi.org/10.1038/s41440-020-0455-8
• Zimmer M.A, Zink A.K, Weißer C.W, Vogt U, Michelsen A, Priebe H.J, et al. Hypernatremia - A Manifestation of COVID-19: A Case Series. A A Pract. 2020; 14(9):e01295. doi: 10.1213/XAA.0000000000001295. PMID: 32909725; PMCID: PMC7409524.
• Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054e62.
• Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens Res. 2020; 43:648–654.
• Fountain J, Lappin S. Physiology, renin angiotensin system. In: Stat Pearls. Treasure Island (FL): Stat Pearls Publishing; 2020.
• Anna Sjöström, Susanne Rysz, Henrik Sjöström, Charlotte Höybye. Hypernatremia is common in patients with severe COVID-19 and indicates a poor prognosis, 23 September 2020, PREPRINT (Version 1) available at Research Square. doi: 10.21203/rs.3.rs-81965/v1+
• Hu W, lv X, Li C, Xu Y, Qi Y, Zhang Z, et al. Disorders of sodium balance and its clinical implications in COVID-19 patients: a multicenter retrospective study. Intern Emerg Med. 2020; 16:1–10. doi: 10.1007/s11739-020-02515-9. Epub ahead of print. PMCID: PMC7563904.
• Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm B.O. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020; 16(6): 297‐298.